KRAS and malignant colon neoplasm: To study a potential role of mutant KRAS/BRAF in Everolimus response, we took the advantage of isogenic colon cancer cell lines with targeted disruption of WT or mutant BRAF alleles, or mutant KRAS knockin or knockout cells.